- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02237807
Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions
September 16, 2020 updated by: Pharmaceutical Research Unit, Jordan
Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions
The purpose of this study is to assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine in plasma and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
An open-label, randomized, two-treatments, three-periods, three-sequences, semi-replicate crossover bioequivalence study with a washout period of at least 14 days between doses.
Healthy, mixed skin Arab & Mediterranean Subjects ages between 18 and 50 years, body-mass index 18.5 to 30.0 kg/m2 inclusive (minimum of 50 kg weight), non-smokers or light smokers (smokers of not more than 10 cigarettes per day).
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amman, Jordan, 11941
- Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy subjects.
- Ethnic Group: Arab & Mediterranean.
- Race: Mixed skin (white & black skin people).
- Age 18-50 years.
- Body-mass index 18.5 to 30.0 kg/m2 inclusive. (minimum of 50 kg weight)
- Subject is available for the whole study period and gave written informed consent.
- Normal Physical examination.
- Vital signs within normal ranges.
- All laboratory screening results within the normal range, or being assessed as clinically Non-significant by the attending physician.
- Normal Kidney & Liver functions test
Exclusion Criteria:
- Women of childbearing potential who don't use any contraceptive method, pregnant and/or lactating women.
- Ethnic Group (Non- Arab &/ or Non- Mediterranean)
- History of severe allergy or allergic reactions to study drug or related drugs or heparin
- Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
- History of serious illness that can impact fate of drugs
- Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease.
- Clinically significant illness 4 weeks before study Period I
- Mental disease.
- Smoking of more than 10 cigarettes per day
- The intake of alcohol and grapefruit during the study.
- The intake of caffeine, xanthenes, or CO2-containing beverages during hospitalization.
- Regular use of medication.
- Having taken medication that could affect the investigated drug product: a) Regular consumption of drugs during the two weeks prior to study initiation day, b) consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates, Carbamazepine, Phenytoin, Amphetamine, Benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine and methadone) during one month before the study initiation.
- Presence of any significant physical or organ abnormality
- Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14 days before study Period I
- Participation in another bioequivalence study and/or Clinical trials within 80 days prior to the start of this study Period I
- Following a special diet (e.g. vegetarian) or dieting one month before the study initiation.
- Subjects with seizures or prior history of seizures.
- Prior history of hypersensitivity to dirithromycin, erythromycin, or other macrolide antibiotics
- Any significant clinical abnormality including HBsAg, HCV, and / or HIV.
- Consumption of grapefruit or grapefruit containing products within 7 days of drug administration
- Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
- Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent significant change in dietary or exercise habits.
- Subjects with history of Liver disease.
- Abnormal Vital Signs.
- Abnormal Kidney and/or Liver functions test.
- Vomiting, Diarrhea on admission
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.
Ve Tic. A. Ş., Turkey one tablet, once
|
|
Experimental: DYNABAC 250 MG ENTERIC COATED TABLET
DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.
Ve Tic. A. Ş., Turkey, two tablets, once
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax Ratio
Time Frame: pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing.
|
Scaled average bioequivalence will be performed.
Bioequivalence limits will be defined and widened according to the reference variance of σw2 within subject variability for the reference for Erythromycylamine.
|
pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing.
|
AUC Ratio
Time Frame: pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing
|
The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00%based on Erythromycylamine
|
pre-dosing and at 1.00, 2.00, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 9.00, 10.00, 12.00, 14.00, 16.00, 20.00, 24.00, 36.00, 48.00, 72.00, 96.00 and 120.00 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Rana T Bustami, Phd.pharmacy, PRU
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
September 9, 2014
First Submitted That Met QC Criteria
September 10, 2014
First Posted (Estimate)
September 11, 2014
Study Record Updates
Last Update Posted (Actual)
September 18, 2020
Last Update Submitted That Met QC Criteria
September 16, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIRI521/PRO-00
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on DYNABAC 250 MG ENTERIC COATED TABLET
-
Pharmaceutical Research Unit, JordanAbdi Ibrahim Ilac San. ve Tic A.S.Completed
-
Pharmaceutical Research Unit, JordanAbdi Ibrahim Ilac San. ve Tic A.S.Completed
-
Pharmaceutical Research Unit, JordanAbdi Ibrahim Ilac San. ve Tic A.S.Completed
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Lexicon PharmaceuticalsCompletedIrritable Bowel SyndromeUnited States
-
Janssen Research & Development, LLCCompletedHealthy ParticipantsUnited States
-
Idorsia Pharmaceuticals Ltd.Completed
-
H. Lundbeck A/SCompletedBioequivalence Study in Healthy SubjectsRussian Federation
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
Max Zeller Soehne AGCompleted